• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference.

作者信息

Piketty Marie-Liesse, Brabant Severine, Souberbielle Jean-Claude, Maruani Gérard, Audrain Christelle, Rothenbuhler Anya, Prié Dominique, Linglart Agnès

机构信息

AP-HP, Department of Functional Explorations, Necker Enfants Malades Hospital, Paris-Centre University, Paris Cedex, France.

AP-HP, Department of Endocrinology and Diabetology for children and Department of Adolescent Medicine, Reference Center for Rare Disorders of the Calcium and Phosphate Metabolism, Filière OSCAR and Platform of Expertise for Rare Diseases Paris-Sud, Bicêtre Paris-Saclay Hospital, Paris Saclay University, Le Kremlin-Bicêtre, France.

出版信息

Clin Chem Lab Med. 2020 Oct 25;58(11):e267-e269. doi: 10.1515/cclm-2020-0460.

DOI:10.1515/cclm-2020-0460
PMID:32653872
Abstract
摘要

相似文献

1
FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference.布罗索尤单抗治疗患者的成纤维细胞生长因子23（FGF23）检测：一种新兴治疗方法可能会引发新的分析干扰。
Clin Chem Lab Med. 2020 Oct 25;58(11):e267-e269. doi: 10.1515/cclm-2020-0460.
2
The effect of burosumab on intact and C-terminal FGF23 measurements.布罗索尤单抗对全段和 C 末端 FGF23 检测的影响。
Clin Endocrinol (Oxf). 2023 Aug;99(2):152-157. doi: 10.1111/cen.14832. Epub 2022 Oct 31.
3
Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.成纤维细胞生长因子 23 相关低磷血症性疾病的最新进展。
Curr Opin Endocrinol Diabetes Obes. 2024 Aug 1;31(4):170-175. doi: 10.1097/MED.0000000000000866. Epub 2024 Apr 30.
4
Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.在使用布罗索尤单抗的时代治疗儿童 X 连锁低磷血症的临床实践指南。
J Paediatr Child Health. 2022 May;58(5):762-768. doi: 10.1111/jpc.15976. Epub 2022 Apr 15.
5
Burosumab for Pediatric X-Linked Hypophosphatemia.布罗索尤单抗治疗儿童 X 连锁低磷血症。
Curr Osteoporos Rep. 2021 Jun;19(3):271-277. doi: 10.1007/s11914-021-00669-9. Epub 2021 May 10.
6
Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.布罗索尤单抗治疗 1-4 岁 X 连锁低磷血症儿童的疗效和安全性：一项多中心、开放标签、2 期临床试验。
Lancet Diabetes Endocrinol. 2019 Mar;7(3):189-199. doi: 10.1016/S2213-8587(18)30338-3. Epub 2019 Jan 9.
7
Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.布罗索尤单抗治疗 X 连锁低磷血症及慢性肾脏病前景。
Curr Opin Nephrol Hypertens. 2020 Sep;29(5):531-536. doi: 10.1097/MNH.0000000000000631.
8
Pharmacological management of X-linked hypophosphataemia.X 连锁低磷血症的药物治疗管理。
Br J Clin Pharmacol. 2019 Jun;85(6):1188-1198. doi: 10.1111/bcp.13763. Epub 2018 Oct 29.
9
Burosumab: First Global Approval.布罗索尤单抗：全球首次获批。
Drugs. 2018 Apr;78(6):707-714. doi: 10.1007/s40265-018-0905-7.
10
Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets.从传统治疗转换为布罗索尤单抗注射治疗有可能预防 X 连锁低磷血症性佝偻病患者的肾钙质沉着症。
J Pediatr Endocrinol Metab. 2021 Apr 12;34(6):791-798. doi: 10.1515/jpem-2020-0734. Print 2021 Jun 25.

引用本文的文献

1
Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort.X连锁低磷血症成年患者对布罗索尤单抗反应的预测因素：来自意大利队列的真实世界数据。
J Endocrinol Invest. 2025 May 5. doi: 10.1007/s40618-025-02596-3.
2
The Diagnosis and Therapy of XLH.XLH的诊断与治疗。
Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w.
3
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.X连锁低磷血症诊断与管理的临床实践建议
Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15.
4
Treatment Advances in Tumor-Induced Osteomalacia.肿瘤诱导性骨软化症的治疗进展
Calcif Tissue Int. 2025 Jan 4;116(1):24. doi: 10.1007/s00223-024-01317-x.
5
Diagnostic approach to rickets: an Endocrine Society of Bengal (ESB) consensus statement.佝偻病的诊断方法：孟加拉内分泌学会（ESB）共识声明
Ann Pediatr Endocrinol Metab. 2024 Oct;29(5):284-307. doi: 10.6065/apem.2448044.022. Epub 2024 Oct 31.
6
Successful Burosumab Treatment in an Adult Patient with X-Linked Hypophosphatemia and Chronic Kidney Disease Stage 3b.成功应用布罗索尤单抗治疗 X 连锁低磷血症合并慢性肾脏病 3b 期成人患者
Calcif Tissue Int. 2024 Mar;114(3):310-314. doi: 10.1007/s00223-023-01169-x. Epub 2024 Jan 9.
7
Determination of iFGF23 Upper Reference Limits (URL) in healthy pediatric population, for its better correct use.确定健康儿科人群中 iFGF23 的上参考限值 (URL)，以更好地正确使用。
Front Endocrinol (Lausanne). 2022 Nov 9;13:1018523. doi: 10.3389/fendo.2022.1018523. eCollection 2022.
8
Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone.X 连锁低磷血症患儿使用布罗索尤单抗和生长激素治疗的生长模式。
Orphanet J Rare Dis. 2022 Nov 12;17(1):412. doi: 10.1186/s13023-022-02562-9.
9
Clinical and genetic characteristics of 29 Chinese patients with X-linked hypophosphatemia.29 例 X 连锁低磷血症患者的临床和遗传学特征。
Front Endocrinol (Lausanne). 2022 Aug 19;13:956646. doi: 10.3389/fendo.2022.956646. eCollection 2022.
10
Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia.成纤维细胞生长因子 23（FGF23）相关磷代谢紊乱的综合管理：X 连锁低磷血症患者评估、诊断和治疗的专家共识声明。
Nat Rev Endocrinol. 2022 Jun;18(6):366-384. doi: 10.1038/s41574-022-00662-x. Epub 2022 Apr 28.